The pH-triggered polyglutamate brush co-delivery of MDR1 and survivin-targeting siRNAs efficiently overcomes multi-drug resistance of NSCLC

Targeting Rab26 to Conquer Cisplatin-Resistant Lung Cancer with Self-Assembled DNA Nanomaterials

“…Co-delivery of siRNA against MDR1 and survivin using DMA-mPEG-b-PG-gspermine (DPPGS) increased apoptosis in resistant cells. 28,29 Administering both anti-survivin and anti-MDR1 hybrid siRNA through the polyglutamine delivery system was another method that sensitized resistant cells to cisplatin. 30,31 Consistent with the above documents, silencing Rab26 by siRNP combined with cisplatin could effectively induce cell apoptosis, suggesting that it might be a novel lung cancer therapy strategy.…”

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies

“…In addition, novel drug delivery methods, including in vivo nanoparticle transport, in vitro modification using nanoparticles, controlled release systems, and biomaterial implantation scaffolds may provide solutions for precisely targeted drug delivery. It has been found that siRNA targeting MDR1 mRNA (siMDR1) and siRNA targeting survivin mRNA (siSurvivin) can be efficiently co‐delivered by a complex nanoparticle while interfering with both genes, and this delivery method targeting mRNA will be a promising method to overcome NSCLC drug resistance 111 . Another study developed a single low‐dose INC280‐loaded nanoparticle, and the results showed that NPs had high anti‐MET/antimetastatic activity, real‐time MRI visualization, and high biocompatibility after a single low dose, achieving multiple delivery of MET‐targeted primary and liver‐metastatic NSCLC, and this new strategy has the potential for widespread applicability in the treatment of advanced NSCLC 112 .…”

“…It has been found that siRNA targeting MDR1 mRNA (siMDR1) and siRNA targeting survivin mRNA (siSurvivin) can be efficiently co‐delivered by a complex nanoparticle while interfering with both genes, and this delivery method targeting mRNA will be a promising method to overcome NSCLC drug resistance. 111 Another study developed a single low‐dose INC280‐loaded nanoparticle, and the results showed that NPs had high anti‐MET/antimetastatic activity, real‐time MRI visualization, and high biocompatibility after a single low dose, achieving multiple delivery of MET‐targeted primary and liver‐metastatic NSCLC, and this new strategy has the potential for widespread applicability in the treatment of advanced NSCLC. 112 Multiple mRNA‐based cancer vaccines are currently undergoing clinical trials (NCT02283320, NCT01792479, NCT01380769, and NCT04381910) based on lipid nanoparticle–mRNA formulations, and RNA vaccines using these lipid nanoparticles further reveal therapeutic options that can be combined with chemotherapy/immunotherapy to improve current lung cancer treatment.…”